98%
921
2 minutes
20
According to data reported by the American Heart Association, more than 5 million diagnostic and therapeutic catheterizations are performed each year in the United States. The number of catheterizations has tripled since 1979. It has been estimated that complications related to the access site result in more than 75,000 surgical procedures annually. Thus, improved management of the access site itself is essential to achieve the greater goals of improved care and reduced cost. Manual compression directly over the site of arterial puncture usually results in adequate hemostasis but has several significant drawbacks. Manual compression is uncomfortable for the patient, is fatiguing and time-consuming for staff, and necessitates several hours of costly in-hospital observation. In addition, it may be ineffective in achieving hemostasis, especially in the setting of systemic anticoagulation or following the use of large-bore devices. Based on the perceived need for an improved method of managing the arterial access site following catheterization, various vascular sealing devices have been developed. There are at least 8 (and the number is increasing) hemostatic vascular closure devices that are currently approved by the FDA for access site closure after femoral arterial catheterization. The chief advantage attributed to vascular sealing devices is accelerated access site hemostasis, even in the setting of anticoagulation, leading to earlier ambulation and hospital discharge following arterial catheterization. The most important drawbacks related to vascular sealing devices include the cost of the devices and the possibility of increased access site complications. Despite the paucity of properly designed studies supporting their use, it is estimated that over one million vascular sealing devices are used annually in the United States, a number that has increased dramatically in the past 5 years.In this review, we present a brief description of the design and function of the most widely used devices, describe the most common mechanisms of failure, and recommend strategies for management of access site complications including hemorrhage, arterial obstruction, and infection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1538574406293760 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Introduction: Patients with aortic aneurysms are at elevated risk of rupture, dissection and death during and after transcatheter aortic valve repair (TAVR), often requiring consideration for endovascular aneurysm repair (EVAR) at the time of TAVR. However, data comparing outcomes of simultaneous versus staged TAVR-EVAR are limited.
Methods: Using the National Inpatient Sample between the years 2018 and 2021, we compared in-hospital outcomes of simultaneous and staged TAVR-EVAR.
Contraception
September 2025
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, 490 Illinois St, San Francisco, CA 94158; Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 1001 Potrero Ave
Objective: Experiencing intimate partner violence (IPV) can negatively impact young people's reproductive autonomy, including making it more challenging to get contraception. This study examined the association between IPV and delays in obtaining contraception in a sample of young women from California and Texas.
Study Design: The data are from a supplementary study to a cluster randomized controlled trial conducted with young people sexually-active within the past year recruited at 29 community colleges during the COVID-19 pandemic (May 2020-May 2023).
Am J Med Sci
September 2025
The George Washington University School of Medicine and Health Sciences, Washington, DC.
Background: In transcatheter aortic valve replacement (TAVR), there is a notable "diabetes discrepancy", where worse/better/similar outcomes were all found for patients with diabetes mellitus (DM). Such divergent findings pose a challenge for clinicians to accurately assess the risks for DM patients undergoing TAVR. We hypothesized the presence of chronic complications could be linked to worse post-TAVR outcomes in DM patients.
View Article and Find Full Text PDFSleep Med Rev
August 2025
Department of Pediatrics, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
Pediatric obstructive sleep apnea (OSA) is a common yet often underdiagnosed condition, partly due to limited access to polysomnography. Mandibular jaw movement (MJM) analysis offers a promising alternative to conventional home sleep apnea testing in children, capturing the dynamic interactions between respiratory drive and upper airway musculature, enabling accurate identification of, and critical insights into, sleep-disordered breathing events. This technical and practical review provides a structured framework for understanding and interpreting MJM signals during sleep in pediatric patients.
View Article and Find Full Text PDFEur J Health Econ
September 2025
Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Background: Policymakers face challenges in developing pricing policies for potentially innovative healthcare technologies (pIHTs) that balance limited budgets, access, and incentives for innovation. This study aimed to map existing evidence and identify knowledge gaps regarding price determinants and pricing policies for pIHTs and their effect on access and sustainability.
Methods: We conducted a scoping Review of scientific and grey literature in English published between 2014 and September 2023 with pre-specified inclusion and exclusion criteria to identify stakeholder-informed price determinants, pricing policies applied by European Economic Area (EEA) or Organisation for Economic Cooperation and Development (OECD) member states, and their access-related impacts.